(Total Views: 722)
Posted On: 01/22/2022 10:17:43 PM
Post# of 155696
Ohm,
I agreed with you that it was weird that Cytodyn didn't track the mTNBC patients and their survival rates.
However, what I really meant to agree with was that Cytodyn would have to confirm any of those data with the FDA in an official format. A phone call to Sarah on Elm Street to see if she is alive doesn't pass muster. A verified data point submitted as part of the study concerning Sarah's status would be required, and take a little time post study.
Perhaps, we have now confirmed substantial improvement over SOC in mTNBC in progreesion free and overall survival.
A partnership in Nash would be cool, but its important to remember all of impending catalysts when lamenting the cancelled Investor Relations Conference Call.
chazzle
IMHO
I agreed with you that it was weird that Cytodyn didn't track the mTNBC patients and their survival rates.
However, what I really meant to agree with was that Cytodyn would have to confirm any of those data with the FDA in an official format. A phone call to Sarah on Elm Street to see if she is alive doesn't pass muster. A verified data point submitted as part of the study concerning Sarah's status would be required, and take a little time post study.
Perhaps, we have now confirmed substantial improvement over SOC in mTNBC in progreesion free and overall survival.
A partnership in Nash would be cool, but its important to remember all of impending catalysts when lamenting the cancelled Investor Relations Conference Call.
chazzle
IMHO
(3)
(0)
